Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and ...

Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products ...

Organogenesis saw revenue and net income drop year over year. The company withdrew annual guidance. Organogenesis is disputing that some of its products should have been excluded from coverage by ...

For the full-year 2025, management updated guidance to project net revenue of $500 million to $525 million, with Advanced Wound Care products expected between $470 million and $490 million and ...

Organogenesis shares have dropped ~42% since my last 'Hold' rating, reflecting ongoing challenges in its core business. Q1 2025 earnings disappointed, with the dominant Advanced Wound Care segment ...

An analyst updated Organogenesis' price target. Competitor Integra LifeSciences said Tuesday it was recalling a product. Organogenesis has a knee osteoarthritis therapy, ReNu, in phase 3 trials.

Robust 218-patient RCT demonstrates statistically superior frequency of wound closure at 12 weeks compared to standard of care (p=.04) Organogenesis believes published study satisfies requirements for ...

The latest price target for Organogenesis Holdings (NASDAQ:ORGO) was reported by Cantor Fitzgerald on August 8, 2025. The analyst firm set a price target for $9.00 expecting ORGO to rise to within 12 ...

Clinical Development Program Appropriate for Rolling BLA Submission Expected by the End of 2025 CANTON, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading ...

Statistically significant (p<0.0477) DFU wound closure at 12 weeks RCT compared PuraPly®AM plus standard of care to standard of care alone Results strengthen existing clinical evidence supporting ...

CANTON, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Organogenesis, a leading regenerative medicine company, today announced it has received U.S. Food and Drug Administration (FDA) 510k Clearance for ...